Withdrawal from THC during adolescence: Sex differences in locomotor activity and anxiety

Behavioural Brain Research

Volumn 231, Issue 1, 2012, Pages 48-59

  Harte Hargrove, Lauren C ^a,b   Dow Edwards, Diana L ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adolescence; Puberty; Sex differences; Spontaneous withdrawal; Tetrahydrocannabinol

Indexed keywords

TETRAHYDROCANNABINOL;

ABSTINENCE; ADOLESCENCE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; CONTROLLED STUDY; DETOXIFICATION; DRUG DEPENDENCE; EMOTION; FEMALE; LOCOMOTION; MALE; MAZE TEST; NONHUMAN; PERINATAL PERIOD; PHYSICAL TOLERANCE; PRIORITY JOURNAL; RAT; SENSITIZATION; SEX DIFFERENCE; SPONTANEOUS WITHDRAWAL;

ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MALE; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; SEX FACTORS; SUBSTANCE WITHDRAWAL SYNDROME; TETRAHYDROCANNABINOL;

EID: 84859077105     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2012.02.048     Document Type: Article

References (119)

1. SAMHSA Results from the 2009 National survey on Drug Use and Health: Summary of National Findings 2011, US Department of Health and Human Services 1.
2. Hoffmann D.E., Weber E. Medical marijuana and the law. New Engl J Med 2010, 362:1453-1457.
3. Iverson L. Cannabis and the brain. Brain 2003, 126:1252-1270.
4. Misner D.L., Sullivan J.M. Mechanism of cannabinoid effects on long-term potentiation and depression in hippocampal CA1 neurons. Neuroscience 1999, 19:6795-6805.
5. Auclair N., Otani S., Soubrie P., Crepel F. Cannabinoids modulates synaptic strength and plasticity at glutamatergic synapses of rat prefrontal cortex pyramidal neurons. J Neurophysiol 2000, 83:3293.
6. Robbe D., Alonso G., Manzoni O.J. Exogenous and endogenous cannabinoids control synaptic transmission in mice nucleus accumbens. Ann NY Acad Sci 2003, 1003:212-225.
7. Azad S.C., Eder M., Marsicano G., Lutz B., Zieglgänsberger W., Rammes G. Activation of the cannabinoid receptor type 1 decreases glutamatergic and GABAergic synaptic transmission in the lateral amygdala of the mouse. Learn Memory 2003, 10:116-128.
8. Katona I., Rancz E.A., Acsady L., Ledent C., Mackie K., Hajos N., et al. Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. J Neurosci 2001, 21:9506-9518.
9. Tan H., Lauzon N.M., Bishop S.F., Bechard M.A., Laviolette S.R. Integrated cannabinoid CB1 receptor transmission within the amygdala-prefrontal cortical pathway modulates neuronal plasticity and emotional memory encoding. Cereb Cortex 2010, 20:1486-1496.
10. Haj-Dahmane S., Shen R.Y. Regulation of plasticity of glutamate synapses by endocannabinoids and the cyclic-AMP/protein kinase A pathway in midbrain dopamine neurons. J Physiol 2010, 588:2589-2604.
11. Belue R.C., Howlett A.C., Westlake T.M., Hutchings D.E. The ontogeny of cannabinoid receptors in the brain of postnatal and aging rats. Neurotoxic Teratol 1995, 17:25-30.
12. Lafenêtre P., Chaouloff F., Marsicano G. The endocannabinoid system in the processing of anxiety and fear and how CB1 receptors may modulate fear extinction. Pharmacol Res 2007, 56:367-381.
13. Haney M., Comer S.D., Ward A.S., Foltin R.W., Fischman M.W. Factors influencing marijuana self-administration by humans. Behav Pharmacol 1997, 8:101-112.
14. Haney M., Ward A.S., Comer S.D., Foltin R.W., Fischman M.W. Abstinence symptoms following oral THC administration to humans. Psychopharmacology 1999, 141:385-394.
15. Haney M., Hart C.L., Vosburg S.K., Nasser J., Bennett A., Zubaran C., et al. Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacology 2004, 29:158-170.
16. Kelly T.H., Foltin R.W., Emurian C.S., Fischman M.W. Are choice and self-administration of marijuana related to delta 9-THC content. Exp Clin Psychopharmacol 1997, 5:74-82.
17. Hart C.L., van Gorp W., Haney M., Foltin R.W., Fischman M.W. Effects of acute smoked marijuana on complex cognitive performance. Neuropsychopharmacology 2001, 25:757-765.
18. Abood M.E., Sauss C., Fan F., Tilton C.L., Martin B.R. Development of behavioral tolerance to delta 9-THC without alteration of cannabinoid receptor binding or mRNA levels in whole brain. Pharmacol Biochem Behav 1993, 46:575-579.
19. Bass C.E., Martin B.R. Time course for the induction and maintenance of tolerance to Delta(9)-tetrahydrocannabinol in mice. Drug Alcohol Depen 2000, 60:113-119.
20. Lichtman A.H., Martin B.R. Cannabinoid tolerance and dependence. Handb Exp Pharmacol 2005, 691-717.
21. D'Souza D.C., Ranganathan M., Braley G., Gueorguieva R., Zimolo Z., Cooper T., et al. Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology 2008, 33:2505-2516.
22. Budney A.J., Hughes J.R., Moore B.A., Vandrey R. Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry 2004, 161:1967-1977.
23. Tanda G., Goldberg S.R. Cannabinoids: reward, dependence, and underlying neurochemical mechanisms - a review of recent preclinical data. Psychopharmacology (Berl) 2003, 169:115-134.
24. Budney A.J., Hughes J.R. The cannabis withdrawal syndrome. Curr Opin Psychiatry 2006, 19:233-238.
25. Fattore L., Altea S., Fratta W. Sex differences in drug addiction: a review of animal and human studies. Women Health (Lond Engl) 2008, 4:51-65.
26. Budney A.J., Vandrey R.G., Hughes J.R., Moore B.A., Bahrenburg B. Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug Alcohol Depend 2007, 86:22-29.
27. Diana M., Melis M., Muntoni A.L., Gessa G.L. Mesolimbic dopaminergic decline after cannabinoid withdrawal. Proc Natl Acad Sci 1998, 95:10269-10273.
28. Compton D.R., Aceto M.D., Lowe J., Martin B.R. In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J Pharmacol Exp Ther 1996, 277:586-594.
29. Degroot A., Nomikos G.G. Genetic deletion and pharmacological blockade of CB1 receptors modulates anxiety in the shock-probe burying test. Eur J Neurosci 2004, 20:1059-1064.
30. Huang P., Liu-Chen L.Y., Kirby L.G. Anxiety-like effects of SR141716-precipitated delta9-tetrahydrocannabinol withdrawal in mice in the elevated plus-maze. Neurosci Lett 2010, 475:165-168.
31. Stewart J.L., McMahon L.R. Rimonabant-induced Delta9-tetrahydrocannabinol withdrawal in rhesus monkeys: discriminative stimulus effects and other withdrawal signs. J Pharmacol Exp Ther 2010, 334:347-356.
32. Leite J.R., Carlini E.A. Failure to obtain cannabis-directed behavior and abstinence syndrome in rats chronically treated with Cannabis sativa extracts. Psychopharmacologia 1974, 36:133-145.
33. Lichtman A.H., Poklis J.L., Poklis A., Wilson D.M., Martin B.R. The pharmacological activity of inhalation exposure to marijuana smoke in mice. Drug Alcohol Depend 2001, 63:107-116.
34. Wilson D.M., Varvel S.A., Harloe J.P., Martin B.R., Lichtman A.H. SR 141716 (Rimonabant) precipitates withdrawal in marijuana-dependent mice. Pharmacol Biochem Behav 2006, 85:105-113.
35. Klausner H.A., Dingell J.V. The metabolism and excretion of delta 9-tetrahydrocannabinol in the rat. Life Sci 1971, 10:49-59.
36. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 2003, 42:327-360.
37. Toennes S.W., Ramaekers J.G., Theunissen E.L., Moeller M.R., Kauert G.F. Comparison of cannabinoid pharmacokinetic properties in occasional and heavy users smoking a marijuana or placebo joint. J Anal Toxicol 2008, 32:470-477.
38. Ehrenreich H., Rinn T., Kunert H.J., Moeller M.R., Poser W., Schilling L., et al. Specific attentional dysfunction in adults following early start of cannabis use. Psychopharmacol (Berl) 1999, 142:295-301.
39. Pope H.G., Gruber A.J., Hudson J.I., Cohane G., Huestis M.A., Yurgelun-Todd D. Early-onset cannabis use and cognitive deficits: what is the nature of the association?. Drug Alcohol Depend 2003, 69:303-310.
40. Schneider M. Puberty as a highly vulnerable developmental period for the consequences of cannabis exposure. Addict Biol 2008, 13(2):253-263.
41. Schneider M., Schömig E., Leweke F.M. Acute and chronic cannabinoid treatment differentially affects recognition memory and social behavior in pubertal and adult rats. Addict Biol 2008, 13(3-4):345-357.
42. Rodríguez de Fonseca F., Ramos J.A., Bonnin A., Fernández-Ruiz J.J. Presence of cannabinoid binding sites in the brain from early postnatal ages. Neuroreport 1993, 4:135-138.
43. Mato S., Del Olmo E., Pazos A. Ontogenetic development of cannabinoid receptor expression and signal transduction functionality in the human brain. Eur J Neurosci 2003, 17:1747-1754.
44. Ellgren M., Artmann A., Tkalych O., Gupta A., Hansen H.S., Hansen S.H., et al. Dynamic changes of the endogenous cannabinoid and opioid mesocorticolimbic systems during adolescence: THC effects. Eur Neuropsychopharmacol 2008, 18:826-834.
45. Fattore L., Fratta W. How important are sex differences in cannabinoid action. Br J Pharmacol 2010, 160:544-548.
46. Rubino T., Parolaro D. Sexually dimorphic effects of cannabinoid compounds on emotion and cognition. Front Behav Neurosci 2011, 5:1-5.
47. Harte L.C., Dow-Edwards D. Sexually dimorphic alterations in locomotion and reversal learning after adolescent tetrahydrocannabinol exposure in the rat. Neurotoxicol Teratol 2010, 32:515-524.
48. Wiley J.L., O'connell M.M., Tokarz M.E., Wright M.J. Pharmacological effects of acute and repeated administration of Delta(9)-tetrahydrocannabinol in adolescent and adult rats. J Pharmacol Exp Ther 2007, 320:1097-1105.
49. Ramos A. Animal models of anxiety: do I need multiple tests. Trend Pharmacol Sci 2008, 29:493-498.
50. Gulinello M., Smith S.S. Anxiogenic effects of neurosteroid exposure: sex differences and altered GABAA receptor pharmacology in adult rats. J Pharmacol Exp Ther 2003, 305(2):541-548.
51. Gulinello M., Gong Q.H., Li X., Smith S.S. Short-term exposure to a neuroactive steroid increases alpha4 GABA(A) receptor subunit levels in association with increased anxiety in the female rat. Brain Res 2001, 910(1-2):55-66.
52. Rodgers R.J., Haller J., Holmes A., Halasz J., Walton T.J., Brain P.F. Corticosterone response to the plus-maze: high correlation with risk assessment in rats and mice. Physiol Behav 1999, 68:47-53.
53. Rodgers R.J., Davli A. Anxiety, defence and the elevated plus maze. Neurosci Biobehav Rev 1997, 21:801-810.
54. Allen-Rowlands C.F., Allen J.P., Greer M.A., Wilson M. Circadian rhythmicity of ACTH and corticosterone in the rat. J Endocrinol Invest 1980, 3:371-377.
55. Spear L.P. The adolescent brain and age-related behavioral manifestations. Neurosci Biobehav Rev 2000, 24:417-463.
56. Whitlow C.T., Freedland C.S., Porrino L.J. Metabolic mapping of the time-dependent effects of delta 9-tetrahydrocannabinol administration in the rat. Psychopharmacology (Berl) 2002, 161:129-136.
57. Long L.E., Chesworth R., Huang X.F., McGregor I.S., Arnold J.C., Karl T. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. Int J Neuropsychopharmacol 2010, 13:861-876.
58. Sañudo-Peña M.C., Romero J., Seale G.E., Fernandez-Ruiz J.J., Walker J.M. Activational role of cannabinoids on movement. Eur J Pharmacol 2000, 391:269-274.
59. Wakley A.A., Craft R.M. Antinociception and sedation following intracerebroventricular administration of Δ9-tetrahydrocannabinol in female vs. male rats. Behav Brain Res 2011, 216:200-206.
60. Jacob W., Yassouridis A., Marsicano G., Monory K., Lutz B., Wotjak C.T. Endocannabinoids render exploratory behaviour largely independent of the test aversiveness: role of glutamatergic transmission. Genes Brain Behav 2009, 8(7):685-698.
61. Marsicano G., Wotjak C.T., Azad S.C., Bisogno T., Rammes G., Cascio M.G. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002, 418(6897):530-534.
62. Haller J., Varga B., Ledent C., Barna I., Freund T.F. Context-dependent effects of CB1 cannabinoid gene disruption on anxiety-like and social behaviour in mice. Eur J Neurosci 2004, 19(7):1906-1912.
63. Huang P., Liu-Chen L.Y., Unterwald E.M., Cowan A. Hyperlocomotion and paw tremors are two highly quantifiable signs of SR141716-precipitated withdrawal from delta9-tetrahydrocannabinol in C57BL/6 mice. Neurosci Lett 2009, 465:66-70.
64. Grillner S., Hellgren J., Ménard A., Saitoh K., Wikström M.A. Mechanisms for selection of basic motor programs - roles for the striatum and pallidum. Trends Neurosci 2005, 28:364-370.
65. Köfalvi A., Rodrigues R.J., Ledent C., Mackie K., Vizi E.S., Cunha R.A., et al. Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis. J Neurosci 2005, 25:2874-2884.
66. Uchigashima M., Narushima M., Fukaya M., Katona I., Kano M., Watanabe M. Subcellular arrangement of molecules for 2-arachidonoyl-glycerol-mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum. J Neurosci 2007, 27:3663-3676.
67. Herkenham M. Cannabinoid receptor localization in brain: relationship to motor and reward systems. Ann N Y Acad Sci 1992, 654:19-32.
68. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 1991, 11:563-583.
69. Hohmann A.G., Herkenham M. Localization of cannabinoid CB(1) receptor mRNA in neuronal subpopulations of rat striatum: a double-label in situ hybridization study. Synapse 2000, 37:71-80.
70. Rodriguez J.J., Mackie K., Pickel V.M. Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus. J Neurosci 2001, 21:823-833.
71. Fernández-Ruiz J. The endocannabinoid system as a target for the treatment of motor dysfunction. Br J Pharmacol 2009, 156:1029-1040.
72. Kreitzer A.C., Regehr W.G. Cerebellar depolarization-induced suppression of inhibition is mediated by endogenous cannabinoids. J Neurosci 2001, 21:174.
73. Ohno-Shosaku T., Maejima T., Kano M. Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron 2001, 29:729-738.
74. Wilson R.I., Nicoll R.A. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 2001, 410:588-592.
75. Rubino T., Guidali C., Vigano D., Realini N., Valenti M., Massi P., et al. CB1 receptor stimulation in specific brain areas differently modulate anxiety-related behaviour. Neuropharmacology 2008, 54:151-160.
76. Burston J.J., Wiley J.L., Craig A.A., Selley D.E., Sim-Selley L.J. Regional enhancement of cannabinoid CB₁ receptor desensitization in female adolescent rats following repeated Delta-tetrahydrocannabinol exposure. Br J Pharmacol 2010, 161(1):103-112.
77. Amal H., Fridman-Rozevich L., Senn R., Strelnikov A., Gafni M., Keren O., et al. Long-term consequences of a single treatment of mice with an ultra-low dose of Delta9-tetrahydrocannabinol (THC). Behav Brain Res 2010, 206:245-253.
78. Okva K.O., Lang A., Nevalainen T., Mauranen K., Vali M., Pokk P. Effects of litter origin and weight on behaviour of outbred NIH/S mice in plus-maze and staircase tests. Scand J Lab Anim Sci 2008, 35(13):127-134.
79. Kirk J.M., de Wit H. Responses to oral delta9-tetrahydrocannabinol in frequent and infrequent marijuana users. Pharmacol Biochem Behav 1999, 63:137-142.
80. Whitlow C.T., Freedland C.S., Porrino L.J. Functional consequences of the repeated administration of Delta9-tetrahydrocannabinol in the rat. Drug Alcohol Depend 2003, 71:169-177.
81. Oviedo A., Glowa J., Herkenham M. Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study. Brain Res 1993, 616:293-302.
82. Romero J., Berrendero F., Manzanares J., Pérez A., Corchero J., Fuentes J.A., et al. Time-course of the cannabinoid receptor down-regulation in the adult rat brain caused by repeated exposure to delta9-tetrahydrocannabinol. Synapse 1998, 30:298-308.
83. Zhuang S., Kittler J., Grigorenko E.V., Kirby M.T., Sim L.J., Hampson R.E., et al. Effects of long-term exposure to delta9-THC on expression of cannabinoid receptor (CB1) mRNA in different rat brain regions. Brain Res Mol Brain Res 1998, 62:141-149.
84. Breivogel C.S., Childers S.R., Deadwyler S.A., Hampson R.E., Vogt L.J., Sim-Selley L.J. Chronic delta9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain. J Neurochem 1999, 73:2447-2459.
85. Vanderschuren L.J., Pierce R.C. Sensitization processes in drug addiction. Curr Top Behav Neurosci 2010, 3:179-195.
86. Rubino T., Viganò D., Massi P., Parolaro D. The psychoactive ingredient of marijuana induces behavioural sensitization. Eur J Neurosci 2001, 14:884-886.
87. Cadoni C., Valentini V., Di Chiara G. Behavioral sensitization to delta 9-tetrahydrocannabinol and cross-sensitization with morphine: differential changes in accumbal shell and core dopamine transmission. J Neurochem 2008, 106:1586-1593.
88. Kolb B., Gorny G., Limebeer C.L., Parker L.A. Chronic treatment with Delta-9-tetrahydrocannabinol alters the structure of neurons in the nucleus accumbens shell and medial prefrontal cortex of rats. Synapse 2006, 60:429-436.
89. Valjent E., Mitchell J.M., Besson M.J., Caboche J., Maldonado R. Behavioural and biochemical evidence for interactions between Delta 9-tetrahydrocannabinol and nicotine. Br J Pharmacol 2002, 135:564-578.
90. Berrendero F., Maldonado R. Involvement of the opoid system in the anxiolytic-like effects induced by Delta(9)-tetrahydrocannabinol. Psychopharmacology (Berl) 2002, 163:111-117.
91. Phan K.L., Angstadt M., Golden J., Onyewuenyi I., Popovska A., de Wit H. Cannabinoid modulation of amygdala reactivity to social signals of threat in humans. J Neurosci 2008, 28:2313-2319.
92. Davis M. Neural systems involved in fear and anxiety measured with fear-potentiated startle. Am Psychol 2006, 61:741-756.
93. Lee T.T., Gorzalka B.B. Timing is everything: evidence for a role of corticolimbic endocannabinoids in modulating hypothalamic-pituitary-adrenal axis activity across developmental periods. Neuroscience 2011, [Epub ahead of print].
94. Hill M.N., McLaughlin R.J., Bingham B., Shrestha L., Lee T.T.Y., Gray J.M., et al. Endogenous cannabinoid signaling is essential for stress adaptation. Proc Natl Acad Sci 2010, 107:9406-9411.
95. Tye K.M., Prakash R., Kim S.U., Fenno L.E., Grosenick L., Zarabi H., et al. Amygdala circuitry mediating reversible and bidirectional control of anxiety. Nature 2011, 471:358-362.
96. Egerton A., Allison C., Brett R.R., Pratt J.A. Cannabinoids and prefrontal cortical function: insights from preclinical studies. Neurosci Biobehav Rev 2006, 30:680-695.
97. Liu B.D.K., Darlington C.L., Smith P.F. Cannabinoid receptor protein expression in the rat hippocampus and entorhinal, perirhinal, postrhinal and temporal cortices: regional variations and age-related changes. Brain Res 2003, 979:235-239.
98. Tsou K., Mackie K., Sañudo-Peña M.C., Walker J.M. Cannabinoid CB1 receptors are localized primarily on cholecystokinin-containing GABAergic interneurons in the rat hippocampal formation. Neuroscience 1999, 93:969-975.
99. Di Marzo V., Berrendero F., Bisogno T., Gonzalez S., Cavalier P., Romero J., et al. Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of delta9-tetrahydrocannabinol-tolerant rats. J Neurochem 2000, 74:1627-1635.
100. Rodríguez de Fonseca F., Carrera M.R., Navarro M., Koob G.F., Weiss F. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science 1997, 276:2050.
101. Caberlotto L., Rimondini R., Hansson A., Eriksson S., Heilig M. Corticotropin-releasing hormone (CRH) mRNA expression in rat central amygdala in cannabinoid tolerance and withdrawal: evidence for an allostatic shift. Neuropsychopharmacology 2004, 29:15-22.
102. Riebe C.J.N., Hill M.N., Lee T.T.Y., Hillard C.J., Gorzalka B.B. Estrogenic regulation of limbic cannabinoid receptor binding. Psychoneuroendocrinology 2010, 35:1265-1269.
103. Monory K., Blaudzun H., Massa F., Kaiser N., Lemberger T., Schütz G., et al. Genetic dissection of behavioural and autonomic effects of Delta(9)-tetrahydrocannabinol in mice. PLoS Biol 2007, 5(10):2354-2368.
104. Rodríguez de Fonseca F., Cebeira M., Ramos J.A., Martín M., Fernández-Ruiz J.J. Cannabinoid receptors in rat brain areas: sexual differences, fluctuations during estrous cycle and changes after gonadectomy and sex steroid replacement. Life Sci 1994, 54:159-170.
105. Narimatsu S., Watanabe K., Yamamoto I., Yoshimura H. Sex difference in the oxidative metabolism of delta 9-tetrahydrocannabinol in the rat. Biochem Pharmacol 1991, 41:1187-1194.
106. Grobin A.C., VanDoren M.J., Porrino L.J., Morrow A.L. Cortical 3 alpha-hydroxy-5 alpha-pregnan-20-one levels after acute administration of Delta-9-tetrahydrocannabino, cocaine and morphine. Psychopharmacology (Berl) 2005, 179:544-550.
107. Shen H., Gong Q.H., Aoki C., Yuan M., Ruderman Y., Dattilo M., et al. Reversal of neurosteroid effects at alpha4beta2delta GABAA receptors triggers anxiety at puberty. Nat Neurosci 2007, 10:469-477.
108. Korenbrot C.C., Huhtaniemi I.T., Weiner R.I. Preputial separation as an external sign of pubertal development in the male rat. Biol Reprod 1977, 17(2):298-303.
109. Engelbregt M.J., van Weissenbruch M.M., Popp-Snijders C., Lips P., Delemarre-van de Waal H.A. Body mass index, body composition, and leptin at onset of puberty in male and female rats after intrauterine growth retardation and after early postnatal food restriction. Pediatr Res 2001, 50(4):474-478.
110. Delemarre-van de Waal H.A., van Coeverden S.C., Engelbregt M.T. Factors affecting onset of puberty. Horm Res 2002, 57(Suppl. 2):15-18.
111. Schneider M., Drews E., Koch M. Behavioral effects in adult rats of chronic prepubertal treatment with the cannabinoid receptor agonist WIN 55,212-2. Behav Pharmacol 2005, 16(5-6):447-454.
112. Schneider M., Koch M. Deficient social and play behavior in juvenile and adult rats after neonatal cortical lesion: effects of chronic pubertal cannabinoid treatment. Neuropsychopharmacology 2005, 30(5):944-957.
113. Fernandes M., Schabarek A., Coper H., Hill R. Modification of delta9-THC-actions by cannabinol and cannabidiol in the rat. Psychopharmacologia 1974, 38:329-338.
114. Hayakawa K., Mishima K., Hazekawa M., Sano K., Irie K., Orito K., et al. Cannabidiol potentiates pharmacological effects of Delta(9)-tetrahydrocannabinol via CB(1) receptor-dependent mechanism. Brain Res 2008, 1188:157-164.
115. Zuardi A.W., Shirakawa I., Finkelfarb E., Karniol I.G. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl) 1982, 76(3):245-250.
116. Fusar-Poli P., Crippa J.A., Bhattacharyya S., Borgwardt S.J., Allen P., Martin-Santos R., et al. Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry 2009, 66(1):95-105.
117. Tuli J.S., Smith J.A., Morton D.B. Stress measurements in mice after transportation. Lab Anim 1995, 29(2):132-138.
118. Laroche J., Gasbarro L., Herman J.P., Blaustein J.D. Reduced behavioral response to gonadal hormones in mice shipped during the peripubertal/adolescent period. Endocrinology 2009, 150(5):2351-2358.
119. van Ruiven R., Meijer G.W., Wiersma A., Baumans V., van Zutphen L.F., Ritskes-Hoitinga J. The influence of transportation stress on selected nutritional parameters to establish the necessary minimum period for adaptation in rat feeding studies. Lab Anim 1998, 32(4):446-456.